Stem Cell Mobilization Treatment Gets Orphan Status from FDA – Drug Discovery & Development
Drug Discovery & DevelopmentThe Orphan Drug Designation was granted for use of BL-8040, in combination with granulocyte colony-stimulating factor (G-CSF), to mobilize human stem cells from the bone marrow to the peripheral blood for collection for autologous or allogeneic …BioLineRx gains orphan status for novel stem cell mobilization treatmentThe Pharma Letter all 10 news articles … Continue reading
